Figure 2.

Representative images from 2 patients with primary refractory mRCC (to prior TKI [Patient 1; images a and b] or ICI therapy [Patient 5; images c and d]) who had a partial response after lenvatinib plus everolimus treatment. Images shown are of the pretreatment scans (a, c), with tumors clearly visible, and the posttreatment scan (b, d), where tumor size is much reduced.

ICI, immune checkpoint inhibitor; mRCC, metastatic renal cell carcinoma; TKI, tyrosine kinase inhibitors.